Several kinds of anthracyclines having y-rhodofnycinone as the aglycone were isolated from Streptomyces cosmosus TMF518, and their derivatives were prepared by chemical modification.
Wetested their differentiation inducing activity in Friend leukemia cells and clarified their structure activity relationship as follows: 1) The aglycone, y-rhodomycinone, had no differentiation inducing activity but was cytotoxic; 2) the compounds with two sugar chains at both C7 and C10 had more potent differentiation inducing activity than those with only a sugar chain at C-10; 3) cosmomycin Cwas the most favorable candidate for an anticancer agent of all anthracyclines tested, because the value of ED50 (cytotoxicity)/ED50 (differentiation) was as high as 3000; and 4) the increase in differentiation inducing activity and cytotoxicity was not always in parallel.
Anthracycline compoundshave become one of the most promising drugs for the treatment of human cancers. Some of them such as adriamycin1} and aclacinomycin2) have been used clinically and been proved to be effective for some kinds of humancancers. The most unfavorable effect of anthracyclines is, like the other chemotherapeutic agents, its toxicity against normal proliferating tissues. Additionally, the cardiotoxic damage is serious, relating to both the total dose and the schedule of drug administration. Therapy with anthracyclines is limited by these toxic characteristics. Therefore, intensive efforts have been made to find less toxic anthracyclines with high antitumorial potency by screening from a cultured broth of Streptomyces and by chemical modification of naturally occurring anthracyclines. However, limited information has been available on the relationship between the structures and biological activities, and in particular, the antitumorial activity and toxicity.
Recently, differentiation-inducing activity has been considered to be a good index in the search for less toxic antitumorial drugs.
Amongmanyanticancer drugs, actinomycin D,3) mitomycin C,4) and bleomycin5) are known to show highly specific inducing activity at low concentrations against Friend leukemia cells and myeloid leukemia cells, and these compounds have been the most effective in cancer treatment.
In the search for less toxic antitumorial compounds, we employed a Friend cell's differentiation system and found several novel compounds, which have been reported elsewhere. Some of these compounds, cosmomycins A, B,6) C and D,7) are y-or j8-rhodomycinone derivatives with one or two sugar chains at the C-7 and C-10 positions. In this paper, we describe the preparation of chemically modified compounds of cosmomycins and the structure-activity relationship, focussing our attention on the protency of differentiation inducing activity.
MATERIALS AND METHODS
Cell lines and culture conditions: Friend cell c1745a was a kind gift from Dr. K. Onodera of The University of The yield of4 from lOmg of5 was 3mg. Compounds 2 and 1 were also prepared from 5 by the same procedure except that hydrolysis was carried out for 1 hour in the case of the 2 and for 3 hours in the case of1. The yields of 2 and 1 were 0.5nig and 0.3mg, respectively, from 10mg of5.
As in the case of4, 1mgof3 was prepared from lOmg of 6 under the same hydrolysis conditions. Compound 9 was prepared by hydrogenolysis of 10 with a catalyst (Pd/H2SO4) under 1 atm of H2 at room temperature for 1 hour. The structures of these compounds were confirmed bŷ -NMR (JEOL JMN-GX-400) and FD-MS (JEOL DX-300) spectroscbpy.
RESULTS
Effect of the sugar chain at C-10 on cytotoxicity and differentiation inducing activity:
The aglycone, y-rhodomycinone, had no differentiation inducing activity, but was cytotoxic as shown in Table II . Its cytotoxic effect was weak with a high ED50 value (I.Sjum) as compared to those of the other tested anthracyclines.
In the cases of almost all the anthracyclines tested, ED50for differentiation was between one fifth and one half of the ED50
for cytotoxicity. The addition of a single sugar, RhN, to the aglycone, y-rhodomycinone, caused differentiation inducing activity. The cytotoxic effect (ED50) was also increased from 2.8/iM to 1.6 /iM.
Further addition of a sugar moiety, deFuc or Rho, enhanced both the cytotoxicity and Table II . Effect of the C-7 and C-10 Sugar Chain on Biological Activities ED50for cytotoxicity is expressed as the dose to kill 50%of the total cells, and ED50for differentiation is the dose to induce half the maximumdifferentiation. differentiation inducing activity. Both the second sugars increased the cytotoxicity by 3~4 times, and the differentiation inducing activity by 5~6 times. Therefore, the degree of increase in cytotoxicity and differentiation inducing activity was almost in parallel. The third sugar of Rho, which was added to -RhN-deFuc and -RhN-Rho to give cosmomycins B and A, respectively, was not always effetive for the enhancement of cytotoxicity or differentiation inducing activity. As compared with 6 to 3, the third sugar Rho did not enhance the cytotoxicity (almost the same) and slightly enhanced the differentiation (1.7 times). In the other cases, namely with 5 and 4, the third sugar Rho decreased the cytotoxicity to about one quarter and the differentiation inducing activity to about a half. Effect of the trisaccharide added at C-7: In addition to the trisaccharide chain at C-10, 7, 8, 10 and ll, with another trisaccharide moiety at C-7 had potent biological activities as compared to their corresponding precursors (Table   II) .
A comparison of the cytotoxicity between 7 and 5, and 8 and 6, indicates that the compounds with RhN-deFuc-Rho at C-7 were more toxic than the compounds without a C-7 sugar chain. A similar effect of the C-7 sugar chain on cytotoxicity was also observed in the case with the addition of RhN-deFuc-CinB; namely, 10 was about ten times more toxic than 9. In all the cases tested, the addition of the C-7 sugar chain made the compoundswith only the C-10 sugar chain more cytotoxic.
As for the differentiation inducing activity, the compoundswith two trisaccharide chains at both C-7 and C-10 were more potent than the compounds with only a sugar chain at C-10. Most remarkably, 7 was 35,000 times more potent than 5.
The addition of RhN-deFuc-Rho to C-7 altered the biological properties of 5 and 6, especially in the case of 5. The structural difference between 5 and 6 was only at the second sugar in the C-10 sugar chain; however, 6 was five times stronger than 5 in both cytotoxicity and differentiation inducing activity. The addition of the same trisaccharide, RhN-deFuc-Rho, at C-7 reversed the biological activities of these compounds. Except for the cases of 5 and 7, the increase in cytotoxicity and differentiation inducing activity occurred almost in parallel with the addition of RhN-deFuc-Rho, or RhN-deFucCinB at C-7. By adding RhN-deFuc-Rho at C-7 of 6, both the cytotoxicity and differentiation inducing activity were increased by about five times. Also, the addition of RhN-deFuc-CinB at C-7 of9, increased the cytotoxicity about by Therefore, the ED50 ratio of cytotoxicity/differentiation may be an index for screening and evaluating the drug candidate. It is necessary to test the in vivo antitumorial activity of the anthracyclines possessing potent differentiation inducing activity.
An example of a desirable antitumorial compound is cosmomycin C, whose ED50 ratio of cytotoxicity/differentiation can be as large as 3,000. In most cases, the addition ofa trisaccharide chain at C-7 increased the biological activity of the anthracyclines, and both the differentiation inducing activity and cytotoxicity were markedly increased to the same extent. Therefore, the ED50 ratio of cytotoxicity/differentiation remained unchanged. The only exception was cosmomycin C, whose ED50 for differentiation was increased by 35,000 times as compared to a 50-fold increase in the ED50value for cytotoxicity. Anthracyclines are known to intercalate to DNA, inhibiting DNAor RNAsynthesis. The finding of an independent increase in ED50 ratio in the case of cosmomycin C suggests that the binding sites of the anthracyclines to DNA for cytotoxicity and induction of differentiation may be different. The structure of a sugar chain is considered to play a role in determining the binding specificity. The mechanisms of differentiation induced by anthracyclines may be related to the inhibition of DNAor RNAsynthesis.
